These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
868 related items for PubMed ID: 22553001
1. Inhibition of RIP1-dependent necrosis prevents adverse cardiac remodeling after myocardial ischemia-reperfusion in vivo. Oerlemans MI, Liu J, Arslan F, den Ouden K, van Middelaar BJ, Doevendans PA, Sluijter JP. Basic Res Cardiol; 2012 Jul; 107(4):270. PubMed ID: 22553001 [Abstract] [Full Text] [Related]
2. Necrostatin-1 alleviates reperfusion injury following acute myocardial infarction in pigs. Koudstaal S, Oerlemans MI, Van der Spoel TI, Janssen AW, Hoefer IE, Doevendans PA, Sluijter JP, Chamuleau SA. Eur J Clin Invest; 2015 Feb; 45(2):150-9. PubMed ID: 25496079 [Abstract] [Full Text] [Related]
3. BLT1 antagonist LSN2792613 reduces infarct size in a mouse model of myocardial ischaemia-reperfusion injury. de Hoog VC, Bovens SM, de Jager SC, van Middelaar BJ, van Duijvenvoorde A, Doevendans PA, Pasterkamp G, de Kleijn DP, Timmers L. Cardiovasc Res; 2015 Dec 01; 108(3):367-76. PubMed ID: 26449403 [Abstract] [Full Text] [Related]
8. Necrostatin-1 inhibits Hmgb1-IL-23/IL-17 pathway and attenuates cardiac ischemia reperfusion injury. Zhang A, Mao X, Li L, Tong Y, Huang Y, Lan Y, Jiang H. Transpl Int; 2014 Oct 01; 27(10):1077-85. PubMed ID: 24810904 [Abstract] [Full Text] [Related]
9. Sodium 4-Phenylbutyrate Attenuates Myocardial Reperfusion Injury by Reducing the Unfolded Protein Response. Takatori O, Usui S, Okajima M, Kaneko S, Ootsuji H, Takashima SI, Kobayashi D, Murai H, Furusho H, Takamura M. J Cardiovasc Pharmacol Ther; 2017 May 01; 22(3):283-292. PubMed ID: 27909014 [Abstract] [Full Text] [Related]
10. Modulation of myocardial injury and collagen deposition following ischaemia-reperfusion by linagliptin and liraglutide, and both together. Wang X, Ding Z, Yang F, Dai Y, Chen P, Theus S, Singh S, Budhiraja M, Mehta JL. Clin Sci (Lond); 2016 Aug 01; 130(15):1353-62. PubMed ID: 27129181 [Abstract] [Full Text] [Related]
11. Activation of RISK and SAFE pathways is not involved in the effects of Cx43 deficiency on tolerance to ischemia-reperfusion injury and preconditioning protection. Sánchez JA, Rodríguez-Sinovas A, Barba I, Miró-Casas E, Fernández-Sanz C, Ruiz-Meana M, Alburquerque-Béjar JJ, García-Dorado D. Basic Res Cardiol; 2013 May 01; 108(3):351. PubMed ID: 23595215 [Abstract] [Full Text] [Related]
12. Ticagrelor protects the heart against reperfusion injury and improves remodeling after myocardial infarction. Ye Y, Birnbaum GD, Perez-Polo JR, Nanhwan MK, Nylander S, Birnbaum Y. Arterioscler Thromb Vasc Biol; 2015 Aug 01; 35(8):1805-14. PubMed ID: 26044583 [Abstract] [Full Text] [Related]
13. CB(2) cannabinoid receptor activation is cardioprotective in a mouse model of ischemia/reperfusion. Montecucco F, Lenglet S, Braunersreuther V, Burger F, Pelli G, Bertolotto M, Mach F, Steffens S. J Mol Cell Cardiol; 2009 May 01; 46(5):612-20. PubMed ID: 19162037 [Abstract] [Full Text] [Related]
14. Combination of necroptosis and apoptosis inhibition enhances cardioprotection against myocardial ischemia-reperfusion injury. Koshinuma S, Miyamae M, Kaneda K, Kotani J, Figueredo VM. J Anesth; 2014 Apr 01; 28(2):235-41. PubMed ID: 24113863 [Abstract] [Full Text] [Related]
15. Myocardial ischemia/reperfusion injury is mediated by leukocytic toll-like receptor-2 and reduced by systemic administration of a novel anti-toll-like receptor-2 antibody. Arslan F, Smeets MB, O'Neill LA, Keogh B, McGuirk P, Timmers L, Tersteeg C, Hoefer IE, Doevendans PA, Pasterkamp G, de Kleijn DP. Circulation; 2010 Jan 05; 121(1):80-90. PubMed ID: 20026776 [Abstract] [Full Text] [Related]
16. NDRG2: a newly identified mediator of insulin cardioprotection against myocardial ischemia-reperfusion injury. Sun Z, Tong G, Ma N, Li J, Li X, Li S, Zhou J, Xiong L, Cao F, Yao L, Wang H, Shen L. Basic Res Cardiol; 2013 May 05; 108(3):341. PubMed ID: 23463182 [Abstract] [Full Text] [Related]
17. RIP1-dependent and independent effects of necrostatin-1 in necrosis and T cell activation. Cho Y, McQuade T, Zhang H, Zhang J, Chan FK. PLoS One; 2011 May 05; 6(8):e23209. PubMed ID: 21853090 [Abstract] [Full Text] [Related]
18. Therapeutic administration of IL-11 exhibits the postconditioning effects against ischemia-reperfusion injury via STAT3 in the heart. Obana M, Miyamoto K, Murasawa S, Iwakura T, Hayama A, Yamashita T, Shiragaki M, Kumagai S, Miyawaki A, Takewaki K, Matsumiya G, Maeda M, Yoshiyama M, Nakayama H, Fujio Y. Am J Physiol Heart Circ Physiol; 2012 Sep 01; 303(5):H569-77. PubMed ID: 22707562 [Abstract] [Full Text] [Related]
19. RNase1 prevents the damaging interplay between extracellular RNA and tumour necrosis factor-α in cardiac ischaemia/reperfusion injury. Cabrera-Fuentes HA, Ruiz-Meana M, Simsekyilmaz S, Kostin S, Inserte J, Saffarzadeh M, Galuska SP, Vijayan V, Barba I, Barreto G, Fischer S, Lochnit G, Ilinskaya ON, Baumgart-Vogt E, Böning A, Lecour S, Hausenloy DJ, Liehn EA, Garcia-Dorado D, Schlüter KD, Preissner KT. Thromb Haemost; 2014 Dec 01; 112(6):1110-9. PubMed ID: 25354936 [Abstract] [Full Text] [Related]
20. Inhibition of receptor-interacting protein 3 upregulation and nuclear translocation involved in Necrostatin-1 protection against hippocampal neuronal programmed necrosis induced by ischemia/reperfusion injury. Yin B, Xu Y, Wei RL, He F, Luo BY, Wang JY. Brain Res; 2015 Jun 03; 1609():63-71. PubMed ID: 25801119 [Abstract] [Full Text] [Related] Page: [Next] [New Search]